Halozyme Therapeutics (HALO) EBIT Margin (2010 - 2026)
Halozyme Therapeutics (HALO) reported EBIT Margin of 48.98% for Q1 2026, down 446.0% year-over-year from 14.16% in Q1 2025, and up 338.22% quarter-over-quarter from 20.56% in Q4 2025.
Halozyme Therapeutics (HALO) EBIT Margin (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has 17 years of EBIT Margin data on file, last reported at 48.98% in Q1 2026.
- EBIT Margin for Q1 2026 came in at 48.98%, down 446.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 33.94% (down 2116.0% YoY), and the FY2025 annual result was 33.58%, down 2073.0% from the prior year.
- EBIT Margin improved to 48.98% in Q1 2026 per HALO's latest filing, from 20.56% in the prior quarter.
- Over five years, EBIT Margin peaked at 64.52% in Q1 2022 and troughed at 20.56% in Q4 2025.
- A 5-year average of 44.04% and a median of 48.78% in 2024 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2023 and 2025: EBIT Margin jumped 2038 bps in 2023, then tumbled 7945 bps in 2025.
- A 5-year view of EBIT Margin shows it stood at 41.05% in 2022, then grew by 7 bps to 43.92% in 2023, then soared by 34 bps to 58.89% in 2024, then slumped by 135 bps to 20.56% in 2025, then soared by 338 bps to 48.98% in 2026.
- Business Quant data shows HALO's EBIT Margin at 48.98% in Q1 2026, 20.56% in Q4 2025, and 61.51% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Halozyme Therapeutics | 8.24 Bn | 7.92 Bn | 297.47 Mn | 48.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.98% |
| Dec 31, 2025 | -20.56% |
| Sep 30, 2025 | 61.51% |
| Jun 30, 2025 | 62.15% |
| Mar 31, 2025 | 53.44% |
| Dec 31, 2024 | 58.89% |
| Sep 30, 2024 | 56.26% |
| Jun 30, 2024 | 50.67% |
| Mar 31, 2024 | 48.78% |
| Dec 31, 2023 | 43.92% |
| Sep 30, 2023 | 40.86% |
| Jun 30, 2023 | 42.73% |
| Mar 31, 2023 | 33.18% |
| Dec 31, 2022 | 41.05% |
| Sep 30, 2022 | 39.86% |
| Jun 30, 2022 | 22.35% |
| Mar 31, 2022 | 64.52% |
| Dec 31, 2021 | 55.42% |
| Sep 30, 2021 | 65.26% |
| Jun 30, 2021 | 68.19% |